Bimatoprost 0,3mg/ml- Eyedrops for lash-lenghtening - Pilot Study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2014-002553-19-AT

Enrollment

Registered

2014-10-01

Start date

2014-12-05

Completion date

Unknown

Last updated

2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

women with too short lashes

Interventions

Trade Name: Lumigan 0,3 mg/ml Pharmaceutical Form: Eye drops INN or Proposed INN: BIMATOPROST CAS Number: 155206-00-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concen

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: men and women from 16 to 99 years infomed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 10 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 5

Exclusion criteria

Exclusion criteria: contact lenses during the study using eye drops pregancy

Design outcomes

Primary

Measure	Time frame
Main Objective: efficiancy of Bimatoprost 03 mg/ml eyedrops on the lash-lenghtening;Secondary Objective: ther are no secondary objectives;Primary end point(s): no endpoints;Timepoint(s) of evaluation of this end point: no endpoints	—

Secondary

Measure	Time frame
Secondary end point(s): no endpoints;Timepoint(s) of evaluation of this end point: no endpoints	—

Countries

Austria

Contacts

Public ContactUniversitätsklinik für Dermatologie

Medizinische Universität Graz, Universitätsklinik für Dermatologie

daisy.kopera@medunigraz.at+433163858181

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026